| Name | Title | Contact Details |
|---|
Pharm-Olam International is a multi-national contract research organization (CRO) offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, Pharm-Olam focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines.
At SI Group, we create smart chemistry that solves global challenges and makes great things possible. We create smart chemistry that solves global challenges and makes great things possible. SI Group is a performance additives and intermediates business. We offer a broad array of products that feed into diverse applications including pharmaceuticals; plastics; oil and gas; and tires, among many others. We create solutions that provide formulators and manufacturers with the ability to increase efficacy, efficiency, productivity, and purity in countless industrial and consumer goods. Our company unites us. So do our values and the approach that we bring into the workplace each day.
DYSIS is a computer-aided colposcope with innovative cervical mapping to help healthcare professionals clearly detect cervical lesions
SCA Pharma is a leading FDA 503B outsourcing facility delivering the highest quality sterile admixtures and pre-filled syringes to hospitals and health systems nationwide. SCA Pharma prides itself on being the most customer- and patient-focused 503B in the industry. Known for its unwavering quality and high-touch customer service, SCA Pharma is headquartered in Little Rock, AR with a sister facility in Windsor, CT. The Windsor facility boasts more than 90,000 square feet of sterile compounding laboratory and manufacturing space while Little Rock is home to SCA Pharma`s 17,000 square foot sterile compounding facility. Both facilities meet or exceed FDA cGMP manufacturing guidelines. SCA Pharma employs more than 500 people across both facilities, as well as a team of sales representatives across the country.
Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis` drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company`s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.